GH241220P40000
- 2.77
- 0.000.00%
Guardant Health Newsroom
Morgan Stanley Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $42
Scotiabank Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $47
A Quick Look at Today's Ratings for Guardant Health(GH.US), With a Forecast Between $34 to $60
Guardant Health (GH) Gets a Buy From Scotiabank
Guardant Health Price Target Raised to $50.00/Share From $48.00 by JP Morgan
Guardant Health Is Maintained at Buy by Goldman Sachs
Stifel Nicolaus Remains a Buy on Guardant Health (GH)
BTIG Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $50
Piper Sandler Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $34
TD Cowen Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $42
Guardant Health: Strong Financial Performance and Growth Prospects Lead to Buy Rating
Morgan Stanley Maintains Guardant Health(GH.US) With Buy Rating, Cuts Target Price to $42
Bernstein Maintains Outperform on Guardant Health, Lowers Price Target to $35
Craig-Hallum Maintains Guardant Health(GH.US) With Buy Rating
Craig-Hallum Keeps Their Buy Rating on Guardant Health (GH)
Guardant Health Is Maintained at Outperform by Leerink Partners
Guardant Health Analyst Ratings
Leerink Partners Maintains Guardant Health(GH.US) With Buy Rating, Cuts Target Price to $50
Morgan Stanley Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $46
Buy Rating on Guardant Health: Significant Market Opportunity and Competitive Edge